Company research
Jasper Therapeutics, Inc.
CIK 1788028Updated Sep 25, 2026
Name history
Amplitude Healthcare Acquisition Corp · through Sep 29, 2021
JSPR price & chart
Loading TradingView…
NASDAQ:JSPR on TradingView ↗About the company
The combined company is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The combined company is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.
In the news
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update ↗
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Nov 14, 2025, 23:46 ET Share this article Share to X Share this article Share to X NEW YORK , Nov. 14, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a glo ↗
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm News provided by The Schall Law Firm Nov 14, 2025, 03:10 ET Share this article Share to X Share this article Share to X LOS ANGELES , Nov. 14, 2025 /PRNewswire/ -- The Schall Law Firm ↗
Recent filings
25-NSE - filed by Nasdaq Stock Market LLC regarding Jasper Therapeutics, Inc.
DEF 14A filing
Entry into a Material Definitive Agreement
Items 1.01
PRE 14A filing
SCHEDULE 13G filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
D filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Other Events
Items 8.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 35,779,000Source | 79,899,000Source | 94,892,000Source | 48,361,000Source |
| Property, Plant and Equipment, NetUSD | 102,000Source | 1,875,000Source | 2,727,000Source | 3,568,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 28,692,000Source | 71,637,000Source | 86,887,000Source | 38,250,000Source |
| Assets, CurrentUSD | 34,645,000Source | 75,811,000Source | 88,938,000Source | 41,731,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,953,000Source | 4,174,000Source | 2,051,000Source | 2,818,000Source |
| Operating Lease, Right-of-Use AssetUSD | 502,000Source | 976,000Source | 1,467,000Source | 1,886,000Source |
| Other Assets, NoncurrentUSD | 113,000Source | 820,000Source | 1,343,000Source | 759,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 31,628,000Source | 18,225,000Source | 16,452,000Source | 12,372,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 3,000Source | 2,000Source | 1,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 320,818,000Source | 302,541,000Source | 248,039,000Source | 141,120,000Source |
| Retained Earnings (Accumulated Deficit)USD | -316,670,000Source | -240,869,000Source | -169,600,000Source | -105,135,000Source |
| Stockholders' Equity Attributable to ParentUSD | 4,151,000Source | 61,674,000Source | 78,440,000Source | 35,989,000Source |
| Liabilities and EquityUSD | 35,779,000Source | 79,899,000Source | 94,892,000Source | 48,361,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 13,200,000Source | 15,237,000Source | 12,374,000Source | 7,065,000Source |
| Operating Lease, Liability, CurrentUSD | 1,235,000Source | 1,089,000Source | 972,000Source | 865,000Source |
| Accounts Payable, CurrentUSD | 6,220,000Source | 4,027,000Source | 4,149,000Source | 1,768,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 724,000Source | 1,814,000Source | 2,786,000Source |
| Other Liabilities, NoncurrentUSD | 2,264,000Source | 2,264,000Source | 2,264,000Source | 2,353,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 37,700,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | 1,108,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,713,000Source | 6,619,000Source | 5,211,000Source | 4,091,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 2,193,000Source | -122,000Source | 2,381,000Source | -2,151,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -77,161,000Source | -62,602,000Source | -52,067,000Source | -45,858,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 5,000Source | -532,000Source | -267,000Source | -576,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | 960,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 34,211,000Source | 47,884,000Source | 100,971,000Source | 55,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 29,109,000Source | 72,054,000Source | 87,304,000Source | 38,667,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 6,619,000Source | — | — |
| Deferred Other Tax Expense (Benefit)USD | — | 327,000Source | — | — |
| Equipment ExpenseUSD | — | — | — | 1,706,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | -11,000Source | — | — |
| General and Administrative ExpenseUSD | 20,779,000Source | 20,418,000Source | 17,076,000Source | 16,569,000Source |
| Income Tax Expense (Benefit)USD | — | 2,000Source | — | — |
| Investment Income, InterestUSD | 1,741,000Source | 5,058,000Source | 5,199,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -75,801,000Source | -71,269,000Source | -64,465,000Source | -37,685,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -71,269,000Source | — | — |
| Nonoperating Income (Expense)USD | 8,082,000Source | 4,970,000Source | — | — |
| Operating Costs and ExpensesUSD | — | — | — | 1,200,000Source |
| Operating ExpensesUSD | 83,883,000Source | 76,239,000Source | 68,861,000Source | 51,196,000Source |
| Operating Lease, Impairment LossUSD | 400,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | -2,187,000Source | -88,000Source | — | 586,000Source |
| Proceeds from Issuance of Common StockUSD | 6,454,000Source | 47,195,000Source | — | 28,000Source |
| Proceeds from Stock Options ExercisedUSD | — | 329,000Source | 388,000Source | 27,000Source |
| Restructuring CostsUSD | 2,253,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | -83,883,000Source | -76,239,000Source | -68,861,000Source | -51,196,000Source |
| Other Nonoperating Income (Expense)USD | -2,187,000Source | -88,000Source | — | 586,000Source |
| Income Tax Expense (Benefit)USD | — | 2,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -75,801,000Source | -71,269,000Source | -64,465,000Source | -37,685,000Source |
| Earnings Per Share, BasicUSD per share | -3.95Source | -4.89Source | -6.18Source | -1.03Source |
| Earnings Per Share, DilutedUSD per share | -3.95Source | -4.89Source | -6.18Source | -1.03Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 19,168,110Source | 14,584,870Source | 10,439,034Source | 36,482,761Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 19,168,110Source | 14,584,870Source | 10,439,034Source | 36,482,761Source |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,056,000Source | 1,373,000Source | — | 975,000Source |
| Equipment ExpenseUSD | — | — | — | 1,706,000Source |
| General and Administrative ExpenseUSD | 20,779,000Source | 20,418,000Source | 17,076,000Source | 16,569,000Source |
| Interest Income (Expense), NetUSD | — | — | -246,000Source | — |
| Investment Income, InterestUSD | 1,741,000Source | 5,058,000Source | 5,199,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -71,269,000Source | — | — |
| Nonoperating Income (Expense)USD | 8,082,000Source | 4,970,000Source | — | — |
| Operating Costs and ExpensesUSD | — | — | — | 1,200,000Source |
| Operating ExpensesUSD | 83,883,000Source | 76,239,000Source | 68,861,000Source | 51,196,000Source |
| Other IncomeUSD | — | — | 4,396,000Source | 13,511,000Source |
| Research and Development ExpenseUSD | 63,104,000Source | 55,821,000Source | 51,785,000Source | 34,627,000Source |
| Restructuring CostsUSD | 2,253,000Source | — | — | — |
Filing attachments
ea030204901ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 ea030204901ex99-1.htm PRESS RELEASE, DATED AUGUST 14, 2026 Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders Completed a concurrent PIPE financing raising $132 million in gross proceeds REDWOOD CITY, Calif., August 14, 2026 (GLOBE NEWSWIRE) - Jasper T…
Read attachment ↗ea029822901ex99-1.htm · 8-K · 2026-07-17
EX-99.1 6 ea029822901ex99-1.htm JASPER THERAPEUTICS, INC. CORPORATE PRESENTATION, DATED JULY 16, 2026 Exhibit 99.1 Exhibit 99.1 2 Safe Harbor Statements Forward-Looking Statements Certain statements contained in this presentation are or may be considered "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as "estimate…
Read attachment ↗ea029831601ex99-1.htm · 8-K · 2026-07-16
EX-99.1 2 ea029831601ex99-1.htm PRESS RELEASE ISSUED ON JULY 16, 2026 Exhibit 99.1 Jasper Therapeutics Announces Merger with Kira Pharmaceuticals Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders Concurrent $132 million private investment with participation from leading life sciences investors and Mirador Therapeutics Kira out-licenses KP-301, a long-acting anti-C5a monoclonal antibo…
Read attachment ↗ea029290901ex99-1.htm · 8-K · 2026-06-01
EX-99.1 2 ea029290901ex99-1.htm PRESS RELEASE, DATED JUNE 1, 2026 Exhibit 99.1 Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value REDWOOD CITY, Calif., June 1, 2026 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chr…
Read attachment ↗ea029079201ex99-1.htm · 8-K · 2026-05-14
EX-99.1 2 ea029079201ex99-1.htm PRESS RELEASE, DATED MAY 14, 2026 Exhibit 99.1 Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chroni…
Read attachment ↗ea028336401ex99-1.htm · 8-K · 2026-03-30
EX-99.1 2 ea028336401ex99-1.htm PRESS RELEASE, DATED MARCH 30, 2026 Exhibit 99.1 Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urtic…
Read attachment ↗